董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dieter Weinand | 男 | Independent Director | 65 | 9.85万美元 | 2.50 | 2026-06-25 |
| Ann Lee | 女 | Independent Director | 64 | 9.78万美元 | 5.00 | 2026-06-25 |
| Anabella Villalobos | 女 | Independent Director | 67 | 9.90万美元 | 4.26 | 2026-06-25 |
| Dov Goldstein | 男 | Independent Director | 58 | 10.90万美元 | 4.26 | 2026-06-25 |
| Arun Swaminathan | 男 | Chief Executive Officer and Director | 57 | 209.10万美元 | 39.46 | 2026-06-25 |
| Wilbur Ross | 男 | Independent Director | 88 | 8.53万美元 | 18.50 | 2026-06-25 |
| Mark Pavao | 男 | Independent Director | 62 | 未披露 | 未持股 | 2026-06-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Snyder | 男 | Chief Financial Officer and Chief Operating Officer | 65 | 136.87万美元 | 41.23 | 2026-06-25 |
| Fred Grossman | 男 | Chief Medical Officer and President | 67 | 145.74万美元 | 34.75 | 2026-06-25 |
| Arun Swaminathan | 男 | Chief Executive Officer and Director | 57 | 209.10万美元 | 39.46 | 2026-06-25 |
董事简历
中英对照 | 中文 | 英文- Dieter Weinand
-
Dieter Weinand自2018年6月起担任董事会成员，自2020年4月起担任主席。从2018年11月至2020年3月，魏南德先生担任赛诺菲公司初级保健执行Vice President，他曾于2014年至2018年担任拜耳公司制药部门总裁。2013年至2014年，Weinand先生担任大冢制药有限公司全球商业化总裁，2010年至2013年，Weinand先生担任辉瑞公司初级保健和亚太地区总裁2001年至2010年，Weinand先生担任百时美施贵宝公司高级副总裁，和Vice President总裁。在加入百时美施贵宝公司之前，魏南德从2000年到2001年担任F.H.福丁公司（F.H.Faulding，Inc.）的高级副总裁，担任华纳-兰伯特公司（Warner-Lambert Company）的董事总经理、Vice President主管和高级主管，该公司于2000年在1994年至2000年期间被辉瑞公司收购，1994年期间在Pharmos Corporation担任Vice President，1990年至1994年期间在Lederle International担任董事、地区业务运营协调员和国际产品经理。Weinand先生此前曾于2013年至2014年担任拜耳股份公司的董事会成员，并于2014年至2018年担任HealthPrize Technologies LLC的董事会成员。Weinand先生于1987年在长岛大学（Long Island University）获得药理学与毒理学硕士学位，并于1982年在康科迪亚学院（Concordia College）获得文学学士学位。
Dieter Weinand has been a member of Replimune Group, Inc.'s Board since June 2018 and has served as the lead independent director of Replimune Group, Inc.'s Board since April 2024. Mr. Weinand was previously the Chairperson of the Board from April 2020 to April 2024. From November 2018 to March 2020, Mr. Weinand served as Executive Vice President, Primary Care of Sanofi S.A. He previously served as President and CEO, Pharmaceutical Division at Bayer AG from 2014 to 2018. From 2013 to 2014, Mr. Weinand was President, Global Commercialization at Otsuka Pharmaceutical Co., Ltd. and from 2010 to 2013 Mr. Weinand was President, Primary Care and Asia Pacific Region at Pfizer Inc. From 2001 to 2010, Mr. Weinand served as President, Senior Vice President, and Vice President of Bristol Myers Squibb Company. Prior to joining Bristol Myers Squibb Company, Mr. Weinand was Senior Vice President at F.H. Faulding, Inc. from 2000 to 2001, Managing Director, Director, Vice President, and Senior Director at Warner Lambert Company, which was acquired by Pfizer Inc. in 2000, during the period from 1994 to 2000, Vice President at Pharmos Corporation during 1994, and Director, Area Business Operations Coordinator, and International Product Manager at Lederle International during the period from 1990 to 1994. Mr. Weinand currently serves on the board of directors of Coya Therapeutics, a Nasdaq listed clinical stage biotechnology company, and as Chairman of the Supervisory Board of Evotec SE, a global life science company listed on both Nasdaq and the Frankfurt Stock Exchange. Previously, Mr. Weinand was a member the board of directors of Reunion Neuroscience, Inc., a clinical stage pharmaceutical company, Bayer AG, from 2013 to 2014, and HealthPrize Technologies LLC, from 2014 to 2018. Mr. Weinand was a director and member of the compensation committee and chair of the audit committee of Field Trip Health Ltd. from October 2019 to July 2022. Mr. Weinand received a M.S. in Pharmacology and Toxicology from Long Island University and a B.A. in Biology from Concordia College. - Dieter Weinand自2018年6月起担任董事会成员，自2020年4月起担任主席。从2018年11月至2020年3月，魏南德先生担任赛诺菲公司初级保健执行Vice President，他曾于2014年至2018年担任拜耳公司制药部门总裁。2013年至2014年，Weinand先生担任大冢制药有限公司全球商业化总裁，2010年至2013年，Weinand先生担任辉瑞公司初级保健和亚太地区总裁2001年至2010年，Weinand先生担任百时美施贵宝公司高级副总裁，和Vice President总裁。在加入百时美施贵宝公司之前，魏南德从2000年到2001年担任F.H.福丁公司（F.H.Faulding，Inc.）的高级副总裁，担任华纳-兰伯特公司（Warner-Lambert Company）的董事总经理、Vice President主管和高级主管，该公司于2000年在1994年至2000年期间被辉瑞公司收购，1994年期间在Pharmos Corporation担任Vice President，1990年至1994年期间在Lederle International担任董事、地区业务运营协调员和国际产品经理。Weinand先生此前曾于2013年至2014年担任拜耳股份公司的董事会成员，并于2014年至2018年担任HealthPrize Technologies LLC的董事会成员。Weinand先生于1987年在长岛大学（Long Island University）获得药理学与毒理学硕士学位，并于1982年在康科迪亚学院（Concordia College）获得文学学士学位。
- Dieter Weinand has been a member of Replimune Group, Inc.'s Board since June 2018 and has served as the lead independent director of Replimune Group, Inc.'s Board since April 2024. Mr. Weinand was previously the Chairperson of the Board from April 2020 to April 2024. From November 2018 to March 2020, Mr. Weinand served as Executive Vice President, Primary Care of Sanofi S.A. He previously served as President and CEO, Pharmaceutical Division at Bayer AG from 2014 to 2018. From 2013 to 2014, Mr. Weinand was President, Global Commercialization at Otsuka Pharmaceutical Co., Ltd. and from 2010 to 2013 Mr. Weinand was President, Primary Care and Asia Pacific Region at Pfizer Inc. From 2001 to 2010, Mr. Weinand served as President, Senior Vice President, and Vice President of Bristol Myers Squibb Company. Prior to joining Bristol Myers Squibb Company, Mr. Weinand was Senior Vice President at F.H. Faulding, Inc. from 2000 to 2001, Managing Director, Director, Vice President, and Senior Director at Warner Lambert Company, which was acquired by Pfizer Inc. in 2000, during the period from 1994 to 2000, Vice President at Pharmos Corporation during 1994, and Director, Area Business Operations Coordinator, and International Product Manager at Lederle International during the period from 1990 to 1994. Mr. Weinand currently serves on the board of directors of Coya Therapeutics, a Nasdaq listed clinical stage biotechnology company, and as Chairman of the Supervisory Board of Evotec SE, a global life science company listed on both Nasdaq and the Frankfurt Stock Exchange. Previously, Mr. Weinand was a member the board of directors of Reunion Neuroscience, Inc., a clinical stage pharmaceutical company, Bayer AG, from 2013 to 2014, and HealthPrize Technologies LLC, from 2014 to 2018. Mr. Weinand was a director and member of the compensation committee and chair of the audit committee of Field Trip Health Ltd. from October 2019 to July 2022. Mr. Weinand received a M.S. in Pharmacology and Toxicology from Long Island University and a B.A. in Biology from Concordia College.
- Ann Lee
-
Ann Lee自2021年10月起担任Prime Medicine，Inc.首席技术官。在此之前，李博士于2019年11月至2021年7月担任生物制药公司百时美施贵宝公司的高级副总裁兼细胞疗法开发和运营主管，担任生物制药公司新基医药公司的细胞疗法开发和运营执行副总裁，2018年4月至2019年11月，并于2017年11月至2018年4月担任生物技术公司Juno Therapeutics, Inc.技术运营执行副总裁。2009年4月至2017年11月，李博士在罗氏集团子公司和生物技术公司基因泰克担任高级副总裁兼制药技术开发全球主管。李博士获得了博士学位。耶鲁大学生物化学工程学士学位和她的学士学位康奈尔大学化学工程博士。
Ann Lee has been a director since June 2021. Dr. Lee is currently the Chief Technical Officer at Prime Medicine, Inc., a position she has held since October 2021. From November 2019 to July 2021, Dr. Lee was SVP and Head of Cell Therapy Development and Operations at Bristol Myer Squibb (NYSE: BMY) ("BMS"), leading teams responsible for the development and commercialization of Breyanzi and Abecma. These two CAR T cell therapy products received FDA licensure in February and March 2021, respectively. Her responsibilities included leading the highly interdependent functions of process and analytical development, manufacturing science and technology (MSAT), manufacturing clinical and commercial supplies, quality, CMC Regulatory, design and implementation of the digital platform, building new facilities, and building the global supply chain at BMS. Previously, from November 2017 to April 2018, she served as Executive Vice President of Technical Operations at Juno Therapeutics, Inc. ("Juno"), which was acquired by BMS via Celgene Corporation. Prior to Juno, from January 2010 to November 2017, Dr. Lee served as Senior Vice President and then Head of Global Technical Development at F. Hoffman La Roche ("Roche") (dual roles at Roche and Genentech). She was responsible for developing and delivering all clinical stage products in Roche's global pipeline, as well as technology transfers and technical support for all commercial products. Prior to Genentech, from June 1989 to September 2005, she was at Merck & Co., Inc. (NYSE: MRK), where she led and developed new vaccines and technologies in research and development, and then was responsible as VP for process engineering and technical operations at 10 chemical sites around the world. Over the course of her career, she has contributed to the development of hundreds of new investigational drugs, and the licensure and commercialization of 25 new vaccines and medicines, with the most recent being two new CAR T cell products for blood cancers. Dr. Lee has authored over 40 scientific publications and holds several patents. She is a member of the National Academy of Engineering, fellow of American Academy of Arts and Sciences, American Institute of Medical and Biological Engineering, and member of the Washington State Academy of Sciences. She serves on the board of directors for the Alliance of Regenerative Medicine. She earned her undergraduate degree from Cornell University and a masters and Ph.D. in Biochemical Engineering with a concentration in molecular biophysics and biochemistry from Yale University. - Ann Lee自2021年10月起担任Prime Medicine，Inc.首席技术官。在此之前，李博士于2019年11月至2021年7月担任生物制药公司百时美施贵宝公司的高级副总裁兼细胞疗法开发和运营主管，担任生物制药公司新基医药公司的细胞疗法开发和运营执行副总裁，2018年4月至2019年11月，并于2017年11月至2018年4月担任生物技术公司Juno Therapeutics, Inc.技术运营执行副总裁。2009年4月至2017年11月，李博士在罗氏集团子公司和生物技术公司基因泰克担任高级副总裁兼制药技术开发全球主管。李博士获得了博士学位。耶鲁大学生物化学工程学士学位和她的学士学位康奈尔大学化学工程博士。
- Ann Lee has been a director since June 2021. Dr. Lee is currently the Chief Technical Officer at Prime Medicine, Inc., a position she has held since October 2021. From November 2019 to July 2021, Dr. Lee was SVP and Head of Cell Therapy Development and Operations at Bristol Myer Squibb (NYSE: BMY) ("BMS"), leading teams responsible for the development and commercialization of Breyanzi and Abecma. These two CAR T cell therapy products received FDA licensure in February and March 2021, respectively. Her responsibilities included leading the highly interdependent functions of process and analytical development, manufacturing science and technology (MSAT), manufacturing clinical and commercial supplies, quality, CMC Regulatory, design and implementation of the digital platform, building new facilities, and building the global supply chain at BMS. Previously, from November 2017 to April 2018, she served as Executive Vice President of Technical Operations at Juno Therapeutics, Inc. ("Juno"), which was acquired by BMS via Celgene Corporation. Prior to Juno, from January 2010 to November 2017, Dr. Lee served as Senior Vice President and then Head of Global Technical Development at F. Hoffman La Roche ("Roche") (dual roles at Roche and Genentech). She was responsible for developing and delivering all clinical stage products in Roche's global pipeline, as well as technology transfers and technical support for all commercial products. Prior to Genentech, from June 1989 to September 2005, she was at Merck & Co., Inc. (NYSE: MRK), where she led and developed new vaccines and technologies in research and development, and then was responsible as VP for process engineering and technical operations at 10 chemical sites around the world. Over the course of her career, she has contributed to the development of hundreds of new investigational drugs, and the licensure and commercialization of 25 new vaccines and medicines, with the most recent being two new CAR T cell products for blood cancers. Dr. Lee has authored over 40 scientific publications and holds several patents. She is a member of the National Academy of Engineering, fellow of American Academy of Arts and Sciences, American Institute of Medical and Biological Engineering, and member of the Washington State Academy of Sciences. She serves on the board of directors for the Alliance of Regenerative Medicine. She earned her undergraduate degree from Cornell University and a masters and Ph.D. in Biochemical Engineering with a concentration in molecular biophysics and biochemistry from Yale University.
- Anabella Villalobos
-
Anabella Villalobos自2021年5月起担任董事。作为Biogen Inc.（Nasdaq：BIIB）（“Biogen”）生物治疗和医学部门的负责人，Villalobos博士负责提供高质量、差异化的候选药物，这些药物会随着临床的发展而成为变革性药物。此外，她还建立了一个新的基因治疗部门，确定了最初的工作方向，包括雇用第一个团队。在加入Biogen公司之前，Villalobos博士在辉瑞公司工作了28年，最近担任药物合成技术和神经科学药物化学副总裁。在辉瑞公司（纽约证券交易所代码：PFE）（Pfizer）任职期间，她是几个药物化学小组的组长，Villalobos博士的团队交付了30多份候选药物，这些药物显示临床生存率有所提高。Villalobos博士在巴拿马大学获得化学学士学位，在堪萨斯大学获得药物化学博士学位，在那里她是Fulbright-Hayes研究员。她曾在耶鲁大学担任过两年的国立卫生研究院合成有机化学博士后研究员。
Anabella Villalobos has been a director since May 2021. Dr. Villalobos is currently the Chief Scientific Officer at Metaphore Biotechnologies, Inc., a position she has held since 2025. From 2017 to 2025, Dr. Villalobos was head of Biotherapeutics and Medicinal Sciences at Biogen Inc. (Nasdaq: BIIB) ("Biogen"), where she was responsible for the delivery of high quality, differentiated drug candidates for neurological, rare, and auto immune diseases across multiple modalities, including small molecules, biologics, oligonucleotides, and gene therapy. Prior to Biogen, Dr. Villalobos was with Pfizer Inc. (NYSE: PFE)("Pfizer") for 28 years where she most recently served as Vice President of Medicinal Synthesis Technologies and Neuroscience Medicinal Chemistry. As the leader of several medicinal chemistry groups throughout her tenure at Pfizer, Dr. Villalobos' teams delivered more than 30 small molecule candidates to combat Alzheimer's disease, Parkinson's disease, schizophrenia, depression, and insomnia. Noteworthy are Ogsiveo (SpringWorks) and tavapadon (AbbVie) which reached the market and proof of concept in Phase 3 studies, respectively. Dr. Villalobos also championed new scientific directions that have improved design practices in medical chemistry including the Central Nervous System Multi Parameter Optimization (CNS MPO). Dr. Villalobos obtained her B.S. in Chemistry at the University of Panama and her Ph.D. in Medicinal Chemistry at the University of Kansas where she was a Fulbright Hayes fellow. She was a National Institutes of Health Postdoctoral Fellow at Yale University in synthetic organic chemistry for two years. - Anabella Villalobos自2021年5月起担任董事。作为Biogen Inc.（Nasdaq：BIIB）（“Biogen”）生物治疗和医学部门的负责人，Villalobos博士负责提供高质量、差异化的候选药物，这些药物会随着临床的发展而成为变革性药物。此外，她还建立了一个新的基因治疗部门，确定了最初的工作方向，包括雇用第一个团队。在加入Biogen公司之前，Villalobos博士在辉瑞公司工作了28年，最近担任药物合成技术和神经科学药物化学副总裁。在辉瑞公司（纽约证券交易所代码：PFE）（Pfizer）任职期间，她是几个药物化学小组的组长，Villalobos博士的团队交付了30多份候选药物，这些药物显示临床生存率有所提高。Villalobos博士在巴拿马大学获得化学学士学位，在堪萨斯大学获得药物化学博士学位，在那里她是Fulbright-Hayes研究员。她曾在耶鲁大学担任过两年的国立卫生研究院合成有机化学博士后研究员。
- Anabella Villalobos has been a director since May 2021. Dr. Villalobos is currently the Chief Scientific Officer at Metaphore Biotechnologies, Inc., a position she has held since 2025. From 2017 to 2025, Dr. Villalobos was head of Biotherapeutics and Medicinal Sciences at Biogen Inc. (Nasdaq: BIIB) ("Biogen"), where she was responsible for the delivery of high quality, differentiated drug candidates for neurological, rare, and auto immune diseases across multiple modalities, including small molecules, biologics, oligonucleotides, and gene therapy. Prior to Biogen, Dr. Villalobos was with Pfizer Inc. (NYSE: PFE)("Pfizer") for 28 years where she most recently served as Vice President of Medicinal Synthesis Technologies and Neuroscience Medicinal Chemistry. As the leader of several medicinal chemistry groups throughout her tenure at Pfizer, Dr. Villalobos' teams delivered more than 30 small molecule candidates to combat Alzheimer's disease, Parkinson's disease, schizophrenia, depression, and insomnia. Noteworthy are Ogsiveo (SpringWorks) and tavapadon (AbbVie) which reached the market and proof of concept in Phase 3 studies, respectively. Dr. Villalobos also championed new scientific directions that have improved design practices in medical chemistry including the Central Nervous System Multi Parameter Optimization (CNS MPO). Dr. Villalobos obtained her B.S. in Chemistry at the University of Panama and her Ph.D. in Medicinal Chemistry at the University of Kansas where she was a Fulbright Hayes fellow. She was a National Institutes of Health Postdoctoral Fellow at Yale University in synthetic organic chemistry for two years.
- Dov Goldstein
-
Dov Goldstein，自2021年3月起担任董事。Goldstein博士在医疗保健行业拥有20多年的战略财务和运营经验。他目前担任BioAge实验室的首席财务官，自2021年11月起担任该职位。在此之前，他于2020-2021年担任Indapta Therapeutics的首席财务官和首席商务官，Indapta Therapeutics是一家生物技术公司，专注于开发一种专有的、现成的、同种异体FcRy缺陷自然杀伤（G-NK）细胞疗法并将其商业化，该疗法可治疗多种类型的癌症。2018-2020年，他在RIGImmune公司担任首席执行官。在此之前，他于2017年至2018年在Schr dinger公司（纳斯达克代码：SDGR）担任首席财务官。2006年至2017年，Goldstein博士在私人投资公司Aisling Capital担任多个领导职务，2014年至2017年担任其管理合伙人。Goldstein博士在2014年至2015年期间担任Loxo Oncology, Inc.（Loxo Oncology）的首席财务官。2000年至2005年，Goldstein博士担任Vicuron制药公司（Vicuron）的首席财务官，通过股权融资筹集了超过2.5亿美元，为公司合伙交易提供了便利，并参与了Vicuron被辉瑞公司以19亿美元收购时的并购过程。在加入Vicuron之前，他是HealthCare Ventures LLC的风险分析总监。Goldstein博士目前在NeuBase Therapeutics, Inc.（Nasdaq：NBSE）和Gain Therapeutics, Inc.（Nasdaq：GANX）的董事会任职，并在各公司的审计委员会担任主席。他之前曾在ADMA生物制品公司（纳斯达克股票代码：ADMA）、Loxo Oncology、Esperion Therapeutics, Inc.（纳斯达克股票代码：ESPR）、Durata Therapeutics, Inc.、Cempra，Inc.以及多家私营公司担任董事。他在斯坦福大学获得生物科学学士学位，在哥伦比亚商学院获得MBA学位，在耶鲁大学医学院获得医学博士学位。选择Goldstein博士担任董事是由于他在生物技术资本市场作为投资者和CFO方面拥有丰富的财务经验。
Dov Goldstein has been a director since March 2021. Dr. Goldstein has over 25 years of strategic financial and operational experience within the healthcare sector. He currently serves as the Chief Financial Officer of BioAge Labs (Nasdaq: BIOA), a position he has held since November 2021. Prior to that, from 2020 2021, he served as the Chief Financial Officer and Chief Business Officer of Indapta Therapeutics. From 2018 2020, he was Chief Executive Officer of RIGImmune, Inc. Prior to that he served as the Chief Financial Officer at Schrdinger, Inc. (Nasdaq: SDGR) from 2017 to 2018. Dr. Goldstein held various leadership roles at Aisling Capital, a private investment firm, from 2006 to 2017, serving as its Managing Partner from 2014 to 2017. Dr. Goldstein served as the Chief Financial Officer of Loxo Oncology, Inc. between 2014 and 2015. From 2000 to 2005, Dr. Goldstein served as Chief Financial Officer of Vicuron Pharmaceuticals, Inc. ("Vicuron"), raising over $250 million in equity financings, facilitating company partnership transactions and participating in the M&A process when Vicuron was acquired by Pfizer for $1.9 billion. Prior to joining Vicuron, he was Director of Venture Analysis at HealthCare Ventures LLC. Dr. Goldstein currently serves on the board of directors of Gain Therapeutics, Inc. (Nasdaq: GANX) where he serves on the audit committee as audit committee chair. He previously served as a director for ADMA Biologics Inc (Nasdaq: ADMA), Loxo Oncology (Nasdaq: LOXO), Esperion Therapeutics, Inc. (Nasdaq: ESPR), Durata Therapeutics, Inc. (Nasdaq: DRTX), Cempra Pharmaceuticals Inc. (Nasdaq: CEMP) and a number of private companies. He received a Bachelor of Science in biological sciences from Stanford University, an MBA from Columbia Business School and an M.D. from Yale School of Medicine. - Dov Goldstein，自2021年3月起担任董事。Goldstein博士在医疗保健行业拥有20多年的战略财务和运营经验。他目前担任BioAge实验室的首席财务官，自2021年11月起担任该职位。在此之前，他于2020-2021年担任Indapta Therapeutics的首席财务官和首席商务官，Indapta Therapeutics是一家生物技术公司，专注于开发一种专有的、现成的、同种异体FcRy缺陷自然杀伤（G-NK）细胞疗法并将其商业化，该疗法可治疗多种类型的癌症。2018-2020年，他在RIGImmune公司担任首席执行官。在此之前，他于2017年至2018年在Schr dinger公司（纳斯达克代码：SDGR）担任首席财务官。2006年至2017年，Goldstein博士在私人投资公司Aisling Capital担任多个领导职务，2014年至2017年担任其管理合伙人。Goldstein博士在2014年至2015年期间担任Loxo Oncology, Inc.（Loxo Oncology）的首席财务官。2000年至2005年，Goldstein博士担任Vicuron制药公司（Vicuron）的首席财务官，通过股权融资筹集了超过2.5亿美元，为公司合伙交易提供了便利，并参与了Vicuron被辉瑞公司以19亿美元收购时的并购过程。在加入Vicuron之前，他是HealthCare Ventures LLC的风险分析总监。Goldstein博士目前在NeuBase Therapeutics, Inc.（Nasdaq：NBSE）和Gain Therapeutics, Inc.（Nasdaq：GANX）的董事会任职，并在各公司的审计委员会担任主席。他之前曾在ADMA生物制品公司（纳斯达克股票代码：ADMA）、Loxo Oncology、Esperion Therapeutics, Inc.（纳斯达克股票代码：ESPR）、Durata Therapeutics, Inc.、Cempra，Inc.以及多家私营公司担任董事。他在斯坦福大学获得生物科学学士学位，在哥伦比亚商学院获得MBA学位，在耶鲁大学医学院获得医学博士学位。选择Goldstein博士担任董事是由于他在生物技术资本市场作为投资者和CFO方面拥有丰富的财务经验。
- Dov Goldstein has been a director since March 2021. Dr. Goldstein has over 25 years of strategic financial and operational experience within the healthcare sector. He currently serves as the Chief Financial Officer of BioAge Labs (Nasdaq: BIOA), a position he has held since November 2021. Prior to that, from 2020 2021, he served as the Chief Financial Officer and Chief Business Officer of Indapta Therapeutics. From 2018 2020, he was Chief Executive Officer of RIGImmune, Inc. Prior to that he served as the Chief Financial Officer at Schrdinger, Inc. (Nasdaq: SDGR) from 2017 to 2018. Dr. Goldstein held various leadership roles at Aisling Capital, a private investment firm, from 2006 to 2017, serving as its Managing Partner from 2014 to 2017. Dr. Goldstein served as the Chief Financial Officer of Loxo Oncology, Inc. between 2014 and 2015. From 2000 to 2005, Dr. Goldstein served as Chief Financial Officer of Vicuron Pharmaceuticals, Inc. ("Vicuron"), raising over $250 million in equity financings, facilitating company partnership transactions and participating in the M&A process when Vicuron was acquired by Pfizer for $1.9 billion. Prior to joining Vicuron, he was Director of Venture Analysis at HealthCare Ventures LLC. Dr. Goldstein currently serves on the board of directors of Gain Therapeutics, Inc. (Nasdaq: GANX) where he serves on the audit committee as audit committee chair. He previously served as a director for ADMA Biologics Inc (Nasdaq: ADMA), Loxo Oncology (Nasdaq: LOXO), Esperion Therapeutics, Inc. (Nasdaq: ESPR), Durata Therapeutics, Inc. (Nasdaq: DRTX), Cempra Pharmaceuticals Inc. (Nasdaq: CEMP) and a number of private companies. He received a Bachelor of Science in biological sciences from Stanford University, an MBA from Columbia Business School and an M.D. from Yale School of Medicine.
- Arun Swaminathan
-
Arun Swaminathan，拥有超过20年的亲力亲为的医疗保健业务主管经验，重点关注企业和业务发展、战略和财务。Swaminathan博士于2023年4月加入Coya，担任首席商务官。他于2024年8月成为董事会成员，并于2024年11月担任首席执行官。在加入Coya之前，Swaminathan博士于2021年9月至2023年3月期间担任Actinium Pharmaceuticals（NYSE：ATNM）的首席商务官（CBO），负责所有业务发展。在Actinium之前，他于2018年12月至2021年9月担任Alteogen（196170.KQ）的CBO。2016年3月至2020年3月，共同创立并担任临床前阶段生物技术公司Lynkogen Inc.的首席执行官。Swaminathan博士在百时美施贵宝和Covance开始了他的临床开发和商业角色的职业生涯。他在匹兹堡大学获得了药物科学博士学位。
Arun Swaminathan has over 20 years of hands on healthcare business executive experience with an emphasis on corporate and business development, strategy, and finance. Dr. Swaminathan joined Coya as Chief Business Officer in April 2023. He became a member of the Board in August 2024 and assumed the role of Chief Executive Officer in November 2024.Prior to joining Coya, Dr. Swaminathan served as Chief Business Officer (CBO) for Actinium Pharmaceuticals (NYSE: ATNM) from September 2021 to March 2023, where he was responsible for all business development. Prior to Actinium, he was the CBO at Alteogen (196170.KQ) from December 2018 to September 2021. From March 2016 to March 2020, he co founded and served as CEO of Lynkogen Inc., a pre clinical stage biotechnology company. Dr. Swaminathan began his career in clinical development and commercial roles of increasing responsibility at Bristol Myers Squibb (NYSE: BMY) and Covance. He obtained his Ph.D. in pharmaceutical sciences from the University of Pittsburgh. - Arun Swaminathan，拥有超过20年的亲力亲为的医疗保健业务主管经验，重点关注企业和业务发展、战略和财务。Swaminathan博士于2023年4月加入Coya，担任首席商务官。他于2024年8月成为董事会成员，并于2024年11月担任首席执行官。在加入Coya之前，Swaminathan博士于2021年9月至2023年3月期间担任Actinium Pharmaceuticals（NYSE：ATNM）的首席商务官（CBO），负责所有业务发展。在Actinium之前，他于2018年12月至2021年9月担任Alteogen（196170.KQ）的CBO。2016年3月至2020年3月，共同创立并担任临床前阶段生物技术公司Lynkogen Inc.的首席执行官。Swaminathan博士在百时美施贵宝和Covance开始了他的临床开发和商业角色的职业生涯。他在匹兹堡大学获得了药物科学博士学位。
- Arun Swaminathan has over 20 years of hands on healthcare business executive experience with an emphasis on corporate and business development, strategy, and finance. Dr. Swaminathan joined Coya as Chief Business Officer in April 2023. He became a member of the Board in August 2024 and assumed the role of Chief Executive Officer in November 2024.Prior to joining Coya, Dr. Swaminathan served as Chief Business Officer (CBO) for Actinium Pharmaceuticals (NYSE: ATNM) from September 2021 to March 2023, where he was responsible for all business development. Prior to Actinium, he was the CBO at Alteogen (196170.KQ) from December 2018 to September 2021. From March 2016 to March 2020, he co founded and served as CEO of Lynkogen Inc., a pre clinical stage biotechnology company. Dr. Swaminathan began his career in clinical development and commercial roles of increasing responsibility at Bristol Myers Squibb (NYSE: BMY) and Covance. He obtained his Ph.D. in pharmaceutical sciences from the University of Pittsburgh.
- Wilbur Ross
-
威尔伯·罗斯，自2023年11月起担任董事。罗斯于2017年2月28日由副总统迈克·彭斯宣誓就任第39任商务部长。罗斯部长是特朗普政府的主要商业代言人，确保美国企业家和企业拥有创造就业和经济机会所需的工具。罗斯部长是WL Ross & Co. LLC的前董事长兼首席战略官，拥有超过55年的投资银行和私募股权经验。他重组了航空公司、服装、汽车零部件、银行、饮料、化工、信用卡、电力、食品服务、家具、石膏、住宅建筑、保险、海上运输、抵押贷款发起和服务、石油和天然气、轨道车制造和租赁、房地产、餐馆、造船厂、钢铁、纺织和卡车运输行业超过4000亿美元的资产。Secretary Ross曾担任100多家公司的董事长或首席董事，这些公司的业务遍及20多个不同的国家。被彭博市场评为全球金融界最具影响力的50人之一，Secretary Ross是唯一一位同时入选私募股权Hall of Fame和Turnaround Management Hall of Fame的人。他此前曾担任纽约市市长鲁迪·朱利安尼的私有化顾问，并被美国总统比尔·克林顿任命为美俄投资基金董事会成员。金大中总统授予罗斯国务卿一枚奖章，以表彰他在韩国金融危机期间给予的帮助。2014年11月，日本天皇授予他旭日金银星勋章。作为慈善家，罗斯国务卿曾担任日本学会主席、布鲁金斯学会受托人和经济研究委员会主席、巴黎装饰艺术博物馆国际顾问成员、布伦海姆基金会受托人、布鲁塞尔勒内·马格利特博物馆美国之友主席和棕榈滩公民协会理事。他还是耶鲁大学管理学院的顾问委员会成员。罗斯国务卿在耶鲁大学获得英国文学本科学位，并以优异成绩毕业于哈佛商学院。
Wilbur Ross has been a director since November 2023. Mr. Ross was sworn in by Vice President Mike Pence as the 39th Secretary of Commerce on February 28, 2017. Secretary Ross was the principal voice of business in the Trump Administration, ensuring that U.S. entrepreneurs and businesses have the tools they need to create jobs and economic opportunity. Secretary Ross is the former Chairman and Chief Strategy Officer of WL Ross & Co. LLC and has over 55 years of investment banking and private equity experience. He has restructured over $400 billion of assets in the airline, apparel, auto parts, banking, beverage, chemical, credit card, electric utility, food service, furniture, gypsum, homebuilding, insurance, marine transport, mortgage origination and servicing, oil and gas, railcar manufacturing and leasing, real estate, restaurant, shipyard, steel, textile and trucking industries. Secretary Ross has been chairman or lead director of more than 100 companies operating in more than 20 different countries. Named by Bloomberg Markets as one of the 50 most influential people in global finance, Secretary Ross is the only person elected to both the Private Equity Hall of Fame and the Turnaround Management Hall of Fame. He previously served as privatization adviser to New York City Mayor Rudy Giuliani and was appointed by President Bill Clinton to the board of the U.S. Russia Investment Fund. President Kim Dae jung awarded Secretary Ross a medal for helping South Korea during its financial crisis and, in November 2014, the Emperor of Japan awarded him the Order of the Rising Sun, Gold and Silver Star.As a philanthropist, Secretary Ross has served as Chairman of the Japan Society, Trustee of the Brookings Institution and Chairman of its Economic Studies Council, International Counsel Member of the Musée des Arts Décoratifs in Paris, Trustee of the Blenheim Foundation, President of the American Friends of the Rene Magritte Museum in Brussels and Director of the Palm Beach Civic Association. He also was an Advisory Board Member of Yale University School of Management. Secretary Ross received his undergraduate degree in English literature from Yale University, and graduated with distinction from Harvard Business School. - 威尔伯·罗斯，自2023年11月起担任董事。罗斯于2017年2月28日由副总统迈克·彭斯宣誓就任第39任商务部长。罗斯部长是特朗普政府的主要商业代言人，确保美国企业家和企业拥有创造就业和经济机会所需的工具。罗斯部长是WL Ross & Co. LLC的前董事长兼首席战略官，拥有超过55年的投资银行和私募股权经验。他重组了航空公司、服装、汽车零部件、银行、饮料、化工、信用卡、电力、食品服务、家具、石膏、住宅建筑、保险、海上运输、抵押贷款发起和服务、石油和天然气、轨道车制造和租赁、房地产、餐馆、造船厂、钢铁、纺织和卡车运输行业超过4000亿美元的资产。Secretary Ross曾担任100多家公司的董事长或首席董事，这些公司的业务遍及20多个不同的国家。被彭博市场评为全球金融界最具影响力的50人之一，Secretary Ross是唯一一位同时入选私募股权Hall of Fame和Turnaround Management Hall of Fame的人。他此前曾担任纽约市市长鲁迪·朱利安尼的私有化顾问，并被美国总统比尔·克林顿任命为美俄投资基金董事会成员。金大中总统授予罗斯国务卿一枚奖章，以表彰他在韩国金融危机期间给予的帮助。2014年11月，日本天皇授予他旭日金银星勋章。作为慈善家，罗斯国务卿曾担任日本学会主席、布鲁金斯学会受托人和经济研究委员会主席、巴黎装饰艺术博物馆国际顾问成员、布伦海姆基金会受托人、布鲁塞尔勒内·马格利特博物馆美国之友主席和棕榈滩公民协会理事。他还是耶鲁大学管理学院的顾问委员会成员。罗斯国务卿在耶鲁大学获得英国文学本科学位，并以优异成绩毕业于哈佛商学院。
- Wilbur Ross has been a director since November 2023. Mr. Ross was sworn in by Vice President Mike Pence as the 39th Secretary of Commerce on February 28, 2017. Secretary Ross was the principal voice of business in the Trump Administration, ensuring that U.S. entrepreneurs and businesses have the tools they need to create jobs and economic opportunity. Secretary Ross is the former Chairman and Chief Strategy Officer of WL Ross & Co. LLC and has over 55 years of investment banking and private equity experience. He has restructured over $400 billion of assets in the airline, apparel, auto parts, banking, beverage, chemical, credit card, electric utility, food service, furniture, gypsum, homebuilding, insurance, marine transport, mortgage origination and servicing, oil and gas, railcar manufacturing and leasing, real estate, restaurant, shipyard, steel, textile and trucking industries. Secretary Ross has been chairman or lead director of more than 100 companies operating in more than 20 different countries. Named by Bloomberg Markets as one of the 50 most influential people in global finance, Secretary Ross is the only person elected to both the Private Equity Hall of Fame and the Turnaround Management Hall of Fame. He previously served as privatization adviser to New York City Mayor Rudy Giuliani and was appointed by President Bill Clinton to the board of the U.S. Russia Investment Fund. President Kim Dae jung awarded Secretary Ross a medal for helping South Korea during its financial crisis and, in November 2014, the Emperor of Japan awarded him the Order of the Rising Sun, Gold and Silver Star.As a philanthropist, Secretary Ross has served as Chairman of the Japan Society, Trustee of the Brookings Institution and Chairman of its Economic Studies Council, International Counsel Member of the Musée des Arts Décoratifs in Paris, Trustee of the Blenheim Foundation, President of the American Friends of the Rene Magritte Museum in Brussels and Director of the Palm Beach Civic Association. He also was an Advisory Board Member of Yale University School of Management. Secretary Ross received his undergraduate degree in English literature from Yale University, and graduated with distinction from Harvard Business School.
- Mark Pavao
-
马克·帕沃自2026年4月起担任董事。他是Biotech Value Advisors的联合创始人，该公司是一家为新兴生物技术公司提供服务的商业化战略咨询公司，自2018年6月以来一直担任该公司的管理合伙人。在其职业生涯的早期，他曾在百时美施贵宝（NYSE：BMY）担任多个高级领导职务，包括2012年11月至2013年10月在阿斯利康/百时美施贵宝联盟内担任美国糖尿病业务总裁，在那里他领导创建了一个独立的商业组织，负责超过10亿美元的年收入和超过2000名员工。他还曾于2012年4月至2013年10月担任心血管与代谢物业务部门高级副总裁，2010年4月至2012年4月担任新兴市场总裁，2008年6月至2012年4月担任全球市场准入与定价高级副总裁，2007年4月至2008年6月担任美国神经科学业务部门高级副总裁。Pavao先生目前担任Medical Knowledge Group董事会主席，自2024年1月起担任Perosphere Technologies董事会成员。他还担任MiracleFeet的董事会成员，这是一家致力于在中低收入国家消除未经治疗的马蹄内翻足的全球性非营利组织，此前他曾担任该组织的董事会主席。在其职业生涯的早期，Pavao先生曾于2004年7月至2006年7月担任Nitromed的销售和营销高级副总裁，是负责推出BiDil的执行领导团队的一员，并于2014年2月至2018年6月担任R Pharm US的首席执行官和联合创始人。他经常为生物技术领导团队和董事会提供商业化战略、投资组合优先顺序和启动准备方面的建议。Pavao先生拥有宾夕法尼亚大学沃顿商学院的MBA学位和北卡罗来纳大学教堂山分校的最高荣誉学士学位，在那里他是一名Morehead学者。
Mark Pavao has been a director since April 2026. He is a Co Founder of Biotech Value Advisors, a commercialization strategy advisory firm serving emerging biotechnology companies and has been Managing Partner with the firm since June 2018. Earlier in his career he held multiple senior leadership roles at Bristol Myers Squibb (NYSE: BMY), including President of the U.S. Diabetes business within the AstraZeneca / Bristol Myers Squibb alliance from November 2012 to October 2013, where he led the creation of a stand alone commercial organization responsible for more than $1 billion in annual revenue and over 2,000 employees. He also served as Senior Vice President of the Cardiovascular & Metabolics business unit from April 2012 to October 2013, President of Emerging Markets from April 2010 to April 2012, Senior Vice President of Global Market Access & Pricing from June 2008 to April 2012, and Senior Vice President of the U.S. Neuroscience business unit from April 2007 to June 2008. Mr. Pavao currently serves as Chair of the Board of Medical Knowledge Group and has been a board member of Perosphere Technologies since January 2024. He also serves on the board of MiracleFeet, a global nonprofit organization dedicated to eliminating untreated clubfoot in low and middle income countries, where he previously served as Board Chair. Earlier in his career, Mr. Pavao served as Senior Vice President of Sales and Marketing at Nitromed from July 2004 to July 2006, where he was part of the executive leadership team responsible for the launch of BiDil, and as Chief Executive Officer and Co Founder of R Pharm US from February 2014 to June 2018. He frequently advises biotechnology leadership teams and boards on commercialization strategy, portfolio prioritization, and launch readiness. Mr. Pavao holds an MBA from The Wharton School of the University of Pennsylvania and a BA with Highest Honors from the University of North Carolina at Chapel Hill, where he was a Morehead Scholar. - 马克·帕沃自2026年4月起担任董事。他是Biotech Value Advisors的联合创始人，该公司是一家为新兴生物技术公司提供服务的商业化战略咨询公司，自2018年6月以来一直担任该公司的管理合伙人。在其职业生涯的早期，他曾在百时美施贵宝（NYSE：BMY）担任多个高级领导职务，包括2012年11月至2013年10月在阿斯利康/百时美施贵宝联盟内担任美国糖尿病业务总裁，在那里他领导创建了一个独立的商业组织，负责超过10亿美元的年收入和超过2000名员工。他还曾于2012年4月至2013年10月担任心血管与代谢物业务部门高级副总裁，2010年4月至2012年4月担任新兴市场总裁，2008年6月至2012年4月担任全球市场准入与定价高级副总裁，2007年4月至2008年6月担任美国神经科学业务部门高级副总裁。Pavao先生目前担任Medical Knowledge Group董事会主席，自2024年1月起担任Perosphere Technologies董事会成员。他还担任MiracleFeet的董事会成员，这是一家致力于在中低收入国家消除未经治疗的马蹄内翻足的全球性非营利组织，此前他曾担任该组织的董事会主席。在其职业生涯的早期，Pavao先生曾于2004年7月至2006年7月担任Nitromed的销售和营销高级副总裁，是负责推出BiDil的执行领导团队的一员，并于2014年2月至2018年6月担任R Pharm US的首席执行官和联合创始人。他经常为生物技术领导团队和董事会提供商业化战略、投资组合优先顺序和启动准备方面的建议。Pavao先生拥有宾夕法尼亚大学沃顿商学院的MBA学位和北卡罗来纳大学教堂山分校的最高荣誉学士学位，在那里他是一名Morehead学者。
- Mark Pavao has been a director since April 2026. He is a Co Founder of Biotech Value Advisors, a commercialization strategy advisory firm serving emerging biotechnology companies and has been Managing Partner with the firm since June 2018. Earlier in his career he held multiple senior leadership roles at Bristol Myers Squibb (NYSE: BMY), including President of the U.S. Diabetes business within the AstraZeneca / Bristol Myers Squibb alliance from November 2012 to October 2013, where he led the creation of a stand alone commercial organization responsible for more than $1 billion in annual revenue and over 2,000 employees. He also served as Senior Vice President of the Cardiovascular & Metabolics business unit from April 2012 to October 2013, President of Emerging Markets from April 2010 to April 2012, Senior Vice President of Global Market Access & Pricing from June 2008 to April 2012, and Senior Vice President of the U.S. Neuroscience business unit from April 2007 to June 2008. Mr. Pavao currently serves as Chair of the Board of Medical Knowledge Group and has been a board member of Perosphere Technologies since January 2024. He also serves on the board of MiracleFeet, a global nonprofit organization dedicated to eliminating untreated clubfoot in low and middle income countries, where he previously served as Board Chair. Earlier in his career, Mr. Pavao served as Senior Vice President of Sales and Marketing at Nitromed from July 2004 to July 2006, where he was part of the executive leadership team responsible for the launch of BiDil, and as Chief Executive Officer and Co Founder of R Pharm US from February 2014 to June 2018. He frequently advises biotechnology leadership teams and boards on commercialization strategy, portfolio prioritization, and launch readiness. Mr. Pavao holds an MBA from The Wharton School of the University of Pennsylvania and a BA with Highest Honors from the University of North Carolina at Chapel Hill, where he was a Morehead Scholar.
高管简历
中英对照 | 中文 | 英文- David Snyder
David Snyder自2022年3月起担任Coya Therapeutics，Inc。首席财务官兼首席运营官。在加入Coya之前，Snyder先生于2020年9月至2022年2月担任DisperSol Technologies，LLC及其全资子公司Aushera BioSciences，Inc.的首席财务官。在加入DisperSol/Aushera之前，2014年7月至2020年9月，Snyder先生在Exicure, Inc.（Nasdaq：XCUR）担任首席财务官，该公司是一家开发核酸疗法的公司。2008年5月至2014年7月，他在Cellular Dynamics公司（纳斯达克股票代码：ICEL）担任首席财务官，该公司开发基于ipsc的干细胞工具和主要的细胞疗法。2007-2008年，斯奈德先生曾担任罗氏NimbleGen公司财务高级副总裁、现场副总裁兼首席财务官。在此之前的2007年，斯奈德先生曾在房地产、软件和制造等公司担任首席财务官的副总裁财务官。在其职业生涯的早期，斯奈德先生曾在金融和房地产投资家Sam Zell工作。他以优异的成绩获得渥太华大学的文学学士学位，并以优异的成绩获得哈佛商学院的工商管理硕士学位，在那里他被指定为乔治·费舍尔·贝克学者。
David Snyder has served as Coya Therapeutics, Inc. Chief Financial Officer and Chief Operating Officer since March 2022. Mr. Snyder has over 25 years' experience as the CFO of public and high growth companies. Prior to joining Coya, Mr. Snyder served as the CFO of DisperSol Technologies, LLC (which subsequently changed its name to AustinPx Pharmaceutics and Manufacturing in 2022). Prior to joining DisperSol, from 2014 2020, Mr. Snyder was the CFO of Exicure, Inc. (Nasdaq: XCUR) a company developing nucleic acid therapeutics. From 2008 to 2014, he was the CFO of Cellular Dynamics, Inc. (Nasdaq: ICEL) a company developing ipsc based stem cell tools and primary cell therapeutics. From 2007 2008, Mr. Snyder served as Senior Vice President of Finance, Site Vice President and Chief Financial Officer of Roche NimbleGen. Prior to 2007, Snyder was CFO of companies in real estate, software, and manufacturing. Early in his career, Mr. Snyder worked for financial and real estate investor Sam Zell. He received his BA summa cum laude from Ottawa University and his M.B.A. with high honors from the Harvard Business School, where he was designated a George Fisher Baker Scholar.- David Snyder自2022年3月起担任Coya Therapeutics，Inc。首席财务官兼首席运营官。在加入Coya之前，Snyder先生于2020年9月至2022年2月担任DisperSol Technologies，LLC及其全资子公司Aushera BioSciences，Inc.的首席财务官。在加入DisperSol/Aushera之前，2014年7月至2020年9月，Snyder先生在Exicure, Inc.（Nasdaq：XCUR）担任首席财务官，该公司是一家开发核酸疗法的公司。2008年5月至2014年7月，他在Cellular Dynamics公司（纳斯达克股票代码：ICEL）担任首席财务官，该公司开发基于ipsc的干细胞工具和主要的细胞疗法。2007-2008年，斯奈德先生曾担任罗氏NimbleGen公司财务高级副总裁、现场副总裁兼首席财务官。在此之前的2007年，斯奈德先生曾在房地产、软件和制造等公司担任首席财务官的副总裁财务官。在其职业生涯的早期，斯奈德先生曾在金融和房地产投资家Sam Zell工作。他以优异的成绩获得渥太华大学的文学学士学位，并以优异的成绩获得哈佛商学院的工商管理硕士学位，在那里他被指定为乔治·费舍尔·贝克学者。
- David Snyder has served as Coya Therapeutics, Inc. Chief Financial Officer and Chief Operating Officer since March 2022. Mr. Snyder has over 25 years' experience as the CFO of public and high growth companies. Prior to joining Coya, Mr. Snyder served as the CFO of DisperSol Technologies, LLC (which subsequently changed its name to AustinPx Pharmaceutics and Manufacturing in 2022). Prior to joining DisperSol, from 2014 2020, Mr. Snyder was the CFO of Exicure, Inc. (Nasdaq: XCUR) a company developing nucleic acid therapeutics. From 2008 to 2014, he was the CFO of Cellular Dynamics, Inc. (Nasdaq: ICEL) a company developing ipsc based stem cell tools and primary cell therapeutics. From 2007 2008, Mr. Snyder served as Senior Vice President of Finance, Site Vice President and Chief Financial Officer of Roche NimbleGen. Prior to 2007, Snyder was CFO of companies in real estate, software, and manufacturing. Early in his career, Mr. Snyder worked for financial and real estate investor Sam Zell. He received his BA summa cum laude from Ottawa University and his M.B.A. with high honors from the Harvard Business School, where he was designated a George Fisher Baker Scholar.
- Fred Grossman
Fred Grossman，自2023年7月起担任总裁兼首席医疗官。他与世界各地的思想领袖有着密切的关系，并与FDA和全球卫生当局就跨治疗领域的许多药物的批准进行了直接谈判。Grossman博士曾在礼来、强生、百时美施贵宝和Sunovion担任高管职务。他曾在Glenmark Pharmaceuticals（BSE；532296）担任总裁兼首席医疗官，这家总部位于印度、年产值15亿美元的全球制药公司负责监督包括仿制药、包括505（b）（2）候选药物在内的复杂仿制药以及下一代生物制剂（包括双特异性抗体）在内的整个管道的开发。他此前还曾在Mesoblast，Inc.（NASDQ：MESO）担任首席医疗官，开发针对炎症性疾病的同种异体细胞疗法。格罗斯曼博士获得精神病学委员会认证，是美国精神病学协会的会员，曾是美国国立卫生研究院（NIH）的会员。他担任过几次学术职务，并撰写了许多科学出版物。
Fred Grossman has been Coya Therapeutics, Inc. President and Chief Medical Officer since July 2023.He has close relationships with thought leaders worldwide and has negotiated directly with the FDA and Global Health Authorities for approval of many drugs across therapeutic areas. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE: 532296), at $1.5 Billion per annum global pharmaceutical company based in India, overseeing development of the entire pipeline including generics, complex generics including 505(b)(2) candidates, and next generation biologics (including bi specific antibodies). He also previously served as Chief Medical Officer at Mesoblast, Inc. (Nasdaq: MESO), developing allogeneic cellular therapies for inflammatory diseases. Dr. Grossman is Board Certified in Psychiatry and a Fellow of the American Psychiatric Association and was a Fellow at the National Institutes of Health (NIH). He has held several academic appointments and authored numerous scientific publications.- Fred Grossman，自2023年7月起担任总裁兼首席医疗官。他与世界各地的思想领袖有着密切的关系，并与FDA和全球卫生当局就跨治疗领域的许多药物的批准进行了直接谈判。Grossman博士曾在礼来、强生、百时美施贵宝和Sunovion担任高管职务。他曾在Glenmark Pharmaceuticals（BSE；532296）担任总裁兼首席医疗官，这家总部位于印度、年产值15亿美元的全球制药公司负责监督包括仿制药、包括505（b）（2）候选药物在内的复杂仿制药以及下一代生物制剂（包括双特异性抗体）在内的整个管道的开发。他此前还曾在Mesoblast，Inc.（NASDQ：MESO）担任首席医疗官，开发针对炎症性疾病的同种异体细胞疗法。格罗斯曼博士获得精神病学委员会认证，是美国精神病学协会的会员，曾是美国国立卫生研究院（NIH）的会员。他担任过几次学术职务，并撰写了许多科学出版物。
- Fred Grossman has been Coya Therapeutics, Inc. President and Chief Medical Officer since July 2023.He has close relationships with thought leaders worldwide and has negotiated directly with the FDA and Global Health Authorities for approval of many drugs across therapeutic areas. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and Sunovion. He served as President and Chief Medical Officer at Glenmark Pharmaceuticals (BSE: 532296), at $1.5 Billion per annum global pharmaceutical company based in India, overseeing development of the entire pipeline including generics, complex generics including 505(b)(2) candidates, and next generation biologics (including bi specific antibodies). He also previously served as Chief Medical Officer at Mesoblast, Inc. (Nasdaq: MESO), developing allogeneic cellular therapies for inflammatory diseases. Dr. Grossman is Board Certified in Psychiatry and a Fellow of the American Psychiatric Association and was a Fellow at the National Institutes of Health (NIH). He has held several academic appointments and authored numerous scientific publications.
- Arun Swaminathan
Arun Swaminathan，拥有超过20年的亲力亲为的医疗保健业务主管经验，重点关注企业和业务发展、战略和财务。Swaminathan博士于2023年4月加入Coya，担任首席商务官。他于2024年8月成为董事会成员，并于2024年11月担任首席执行官。在加入Coya之前，Swaminathan博士于2021年9月至2023年3月期间担任Actinium Pharmaceuticals（NYSE：ATNM）的首席商务官（CBO），负责所有业务发展。在Actinium之前，他于2018年12月至2021年9月担任Alteogen（196170.KQ）的CBO。2016年3月至2020年3月，共同创立并担任临床前阶段生物技术公司Lynkogen Inc.的首席执行官。Swaminathan博士在百时美施贵宝和Covance开始了他的临床开发和商业角色的职业生涯。他在匹兹堡大学获得了药物科学博士学位。
Arun Swaminathan has over 20 years of hands on healthcare business executive experience with an emphasis on corporate and business development, strategy, and finance. Dr. Swaminathan joined Coya as Chief Business Officer in April 2023. He became a member of the Board in August 2024 and assumed the role of Chief Executive Officer in November 2024.Prior to joining Coya, Dr. Swaminathan served as Chief Business Officer (CBO) for Actinium Pharmaceuticals (NYSE: ATNM) from September 2021 to March 2023, where he was responsible for all business development. Prior to Actinium, he was the CBO at Alteogen (196170.KQ) from December 2018 to September 2021. From March 2016 to March 2020, he co founded and served as CEO of Lynkogen Inc., a pre clinical stage biotechnology company. Dr. Swaminathan began his career in clinical development and commercial roles of increasing responsibility at Bristol Myers Squibb (NYSE: BMY) and Covance. He obtained his Ph.D. in pharmaceutical sciences from the University of Pittsburgh.- Arun Swaminathan，拥有超过20年的亲力亲为的医疗保健业务主管经验，重点关注企业和业务发展、战略和财务。Swaminathan博士于2023年4月加入Coya，担任首席商务官。他于2024年8月成为董事会成员，并于2024年11月担任首席执行官。在加入Coya之前，Swaminathan博士于2021年9月至2023年3月期间担任Actinium Pharmaceuticals（NYSE：ATNM）的首席商务官（CBO），负责所有业务发展。在Actinium之前，他于2018年12月至2021年9月担任Alteogen（196170.KQ）的CBO。2016年3月至2020年3月，共同创立并担任临床前阶段生物技术公司Lynkogen Inc.的首席执行官。Swaminathan博士在百时美施贵宝和Covance开始了他的临床开发和商业角色的职业生涯。他在匹兹堡大学获得了药物科学博士学位。
- Arun Swaminathan has over 20 years of hands on healthcare business executive experience with an emphasis on corporate and business development, strategy, and finance. Dr. Swaminathan joined Coya as Chief Business Officer in April 2023. He became a member of the Board in August 2024 and assumed the role of Chief Executive Officer in November 2024.Prior to joining Coya, Dr. Swaminathan served as Chief Business Officer (CBO) for Actinium Pharmaceuticals (NYSE: ATNM) from September 2021 to March 2023, where he was responsible for all business development. Prior to Actinium, he was the CBO at Alteogen (196170.KQ) from December 2018 to September 2021. From March 2016 to March 2020, he co founded and served as CEO of Lynkogen Inc., a pre clinical stage biotechnology company. Dr. Swaminathan began his career in clinical development and commercial roles of increasing responsibility at Bristol Myers Squibb (NYSE: BMY) and Covance. He obtained his Ph.D. in pharmaceutical sciences from the University of Pittsburgh.